Abstract
The vascular system has an important function of supplying tissues with oxygen and nutrients and clearing waste products. Therefore, the microvasculature must be sufficiently permeable to allow the free, bidirectional passage of small molecules and gases and, to a lesser extent, of plasma proteins. It is well recognized that vascular endothelial growth factor (VEGF) can increase vascular permeability, thus playing important roles in variety of disorders, including diabetic retinopathy, nephrotic syndrome, brain edema, acute respiratory distress syndrome, and sepsis-associated hypotension. However, how vascular permeability is controlled by anti-permeable factors is not fully understood. We have recently found that pigment epithelium-derived factor (PEDF), a 50kD glycoprotein, inhibits retinal, renal and brain hyperpermeability by counteracting the biological actions of VEGF. In this review, we discuss about the pathophysiological role of PEDF in vascular permeability, especially focusing on retinal- renal disorders.
Keywords: Diabetic retinopathy, hyperpermeability, nephrotic syndrome, PEDF, VEGF
Current Molecular Medicine
Title: Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders
Volume: 10 Issue: 3
Author(s): S. Ueda, S.-I. Yamagishi and S. Okuda
Affiliation:
Keywords: Diabetic retinopathy, hyperpermeability, nephrotic syndrome, PEDF, VEGF
Abstract: The vascular system has an important function of supplying tissues with oxygen and nutrients and clearing waste products. Therefore, the microvasculature must be sufficiently permeable to allow the free, bidirectional passage of small molecules and gases and, to a lesser extent, of plasma proteins. It is well recognized that vascular endothelial growth factor (VEGF) can increase vascular permeability, thus playing important roles in variety of disorders, including diabetic retinopathy, nephrotic syndrome, brain edema, acute respiratory distress syndrome, and sepsis-associated hypotension. However, how vascular permeability is controlled by anti-permeable factors is not fully understood. We have recently found that pigment epithelium-derived factor (PEDF), a 50kD glycoprotein, inhibits retinal, renal and brain hyperpermeability by counteracting the biological actions of VEGF. In this review, we discuss about the pathophysiological role of PEDF in vascular permeability, especially focusing on retinal- renal disorders.
Export Options
About this article
Cite this article as:
Ueda S., Yamagishi S.-I. and Okuda S., Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders, Current Molecular Medicine 2010; 10 (3) . https://dx.doi.org/10.2174/156652410791065291
DOI https://dx.doi.org/10.2174/156652410791065291 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melatonin, a Potential Therapeutic Agent for Smooth Muscle-Related Pathological Conditions and Aging
Current Medicinal Chemistry Prophylactic Neuroprotection
Current Drug Targets Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets Cardiac Workup of Ischemic Stroke
Current Cardiology Reviews Aligning Animal Models of Clinical Germinal Matrix Hemorrhage, From Basic Correlation to Therapeutic Approach
Current Drug Targets Pharmacological and Toxicological Profile of Harmane-β-Carboline Alkaloid: Friend or Foe
Current Drug Metabolism Thrombotic Thrombocytopenic Purpura, from the Perspectives of a Pediatrician
Current Pediatric Reviews Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Snake Venom Peptides and Low Mass Proteins: Molecular Tools and Therapeutic Agents
Current Medicinal Chemistry Rho Kinase Inhibitors and Novel Ocular Drug Delivery Systems- A Revolutionary Step Towards the Treatment of Glaucoma
Current Drug Delivery Subject Index to Volume 4
Current Drug Targets - Cardiovascular & Hematological Disorders Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology Invited Editorial: Malaria by <i>Plasmodium knowlesi</i>, A Zoonosis Transmitted by Vectors
Recent Patents on Anti-Infective Drug Discovery Comparison of Intra and Post-operative Sedation Efficacy of Dexmedetomidinemidazolam and Dexmedetomidine-propofol for Major Abdominal Surgery
Current Drug Metabolism Towards the Development of Anticancer Drugs from Andrographolide: Semisynthesis, Bioevaluation, QSAR Analysis and Pharmacokinetic Studies
Current Topics in Medicinal Chemistry Prevalence, Presentation and Outcome of Secondary Bloodstream Infections among COVID-19 Patients
Infectious Disorders - Drug Targets Current Role and Future Perspectives of Radioiodinated MIBG in the Evaluation of Dementia with Lewy Bodies
Current Radiopharmaceuticals Protein disulfide isomerase and Nox: new partners in redox signaling
Current Pharmaceutical Design The Metabolic Approach in Patients with Heart Failure: Effects on Left Ventricle Remodeling
Current Pharmaceutical Design Editorial: [Hot Topic: Chromogranin A at the Crossroads of Health and Disease]
Current Medicinal Chemistry